Journal articles: 'Regulatory T cell'

1

ZHOU, Zhou, Juan FENG, and Xian WANG. "Regulatory T Cell Differentiation and Regulators." ACTA BIOPHYSICA SINICA 28, no. 2 (2012): 93. http://dx.doi.org/10.3724/sp.j.1260.2012.20002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ait-Oufella, Hafid, and Alain Tedgui. "Regulatory T-Cell Plasticity." Circulation Research 118, no. 10 (May 13, 2016): 1461–63. http://dx.doi.org/10.1161/circresaha.116.308805.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bashyam, Hema. "Regulatory T cell brakes." Journal of Experimental Medicine 205, no. 3 (February 18, 2008): 505. http://dx.doi.org/10.1084/jem.2053iti1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Savage, Peter A., David E. J. Klawon, and Christine H. Miller. "Regulatory T Cell Development." Annual Review of Immunology 38, no. 1 (April 26, 2020): 421–53. http://dx.doi.org/10.1146/annurev-immunol-100219-020937.

Full text

Abstract:

Foxp3-expressing CD4+ regulatory T (Treg) cells play key roles in the prevention of autoimmunity and the maintenance of immune homeostasis and represent a major barrier to the induction of robust antitumor immune responses. Thus, a clear understanding of the mechanisms coordinating Treg cell differentiation is crucial for understanding numerous facets of health and disease and for developing approaches to modulate Treg cells for clinical benefit. Here, we discuss current knowledge of the signals that coordinate Treg cell development, the antigen-presenting cell types that direct Treg cell selection, and the nature of endogenous Treg cell ligands, focusing on evidence from studies in mice. We also highlight recent advances in this area and identify key unanswered questions.

APA, Harvard, Vancouver, ISO, and other styles

5

Rosenblum, Michael D., Sing Sing Way, and Abul K. Abbas. "Regulatory T cell memory." Nature Reviews Immunology 16, no. 2 (December 21, 2015): 90–101. http://dx.doi.org/10.1038/nri.2015.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ward-Hartstonge, Kirsten A., and Ajithkumar Vasanthakumar. "Regulatory T-cell heterogeneity." Clinical & Translational Immunology 7, no. 3 (2018): e01012. http://dx.doi.org/10.1002/cti2.1012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Scott, David W. "T regulatory cells turn on T regulatory cells." Blood 114, no. 19 (November 5, 2009): 3975–76. http://dx.doi.org/10.1182/blood-2009-09-241406.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Yano, Hiroki, Takashi Ishida, Atsushi Inagaki, Toshihiko Ishii, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Atae Utsunomiya, and Ryuzo Ueda. "Regulatory T-cell function of adult T-cell leukemia/lymphoma cells." International Journal of Cancer 120, no. 9 (2007): 2052–57. http://dx.doi.org/10.1002/ijc.22536.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Barchet, Winfried, Jeffrey D. Price, Marina Cella, Marco Colonna, Sandra K. MacMillan, J. Perren Cobb, Paul A. Thompson, Kenneth M. Murphy, John P. Atkinson, and Claudia Kemper. "Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation." Blood 107, no. 4 (February 15, 2006): 1497–504. http://dx.doi.org/10.1182/blood-2005-07-2951.

Full text

Abstract:

Concurrent activation of the T-cell receptor (TCR) and complement regulator CD46 on human CD4+ T lymphocytes induces Tr1-like regulatory T cells that suppress through IL-10 secretion bystander T-cell proliferation. Here we show that, despite their IL-10 production, CD46-induced T-regulatory T cells (Tregs) do not suppress the activation/maturation of dendritic cells (DCs). DC maturation by complement/CD46-induced Tregs is mediated through simultaneous secretion of GM-CSF and soluble CD40L, factors favoring DC differentiation and reversing inhibitory effects of IL-10. Thus, CD46-induced Tregs produce a distinct cytokine profile that inhibits T-cell responses but leaves DC activation unimpaired. Such “DC-sparing” Tregs could be desirable at host/environment interfaces such as the gastrointestinal tract where their specific cytokine profile provides a mechanism that ensures unresponsiveness to commensal bacteria while maintaining reactivity to invading pathogens.

APA, Harvard, Vancouver, ISO, and other styles

10

Pacholczyk, Rafal, and Joanna Kern. "The T-cell receptor repertoire of regulatory T cells." Immunology 125, no. 4 (December 2008): 450–58. http://dx.doi.org/10.1111/j.1365-2567.2008.02992.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

James, Edd, Ian Bailey, Emma Reeves, and Tim Elliott. "Differential T cell suppression through regulatory T cells (66.43)." Journal of Immunology 186, no. 1_Supplement (April 1, 2011): 66.43. http://dx.doi.org/10.4049/jimmunol.186.supp.66.43.

Full text

Abstract:

Abstract Depletion of regulatory T cells in the CT26 murine tumour model stimulates a robust protective T cell response which is also protective to challenge with other tumours of different histological origins. We have characterised a cross-protective antigen, GSW11 (GGPESFYCASW) presented by H-2Dd. This antigen was found to be encoded within the env (gp90) gene of an endogenous retrovirus emv-1 (MuLV), previously shown to encode other CT26 antigens. Further characterisation of GSW11-specific T cell responses has shown them to be suppressed by Tregs and are absent in CT26 challenged mice. In comparison, AH1-specific T cells (AH1 is a previously characterised CT26 antigen) are not suppressed. Here we show that the GSW11-specific T cell responses are present in CT26 challenged Treg replete mice for a limited period in the tumour of challenged mice. Characterisation of the AH1 and GSW11-specific T cells infiltrating the CT26 tumour reveal differences in expression of several molecules associated with cell survival and activation. These expression profiles provide an intriguing explanation for the differential suppression of tumour-specific T cells in vivo.

APA, Harvard, Vancouver, ISO, and other styles

12

Mohammadnia-Afrouzi, Mousa, Mehdi Shahbazi, Sedigheh Baleghi Damavandi, Ghasem Faghanzadeh Ganji, and Soheil Ebrahimpour. "Regulatory T-cell: Regulator of Host Defense in Infection." Journal of Molecular Biology Research 7, no. 1 (February 4, 2017): 9. http://dx.doi.org/10.5539/jmbr.v7n1p9.

Full text

Abstract:

Based on diverse activities and production of several cytokines, T lymphocytes and T helper cells are divided into Th1, Th2, Th17 and regulatory T-cell (T regs) subsets based on diverse activities and production of several cytokines. Infectious agents can escape from host by modulation of immune responses as effector T-cells and Tregs. Thus, regulatory T-cells play a critical role in suppression of immune responses to infectious agents such as viruses, bacteria, parasites and fungi and as well as preserving immune homeostasis. However, regulatory T-cell responses can advantageous for the body by minimizing the tissue-damaging effects. The following subsets of regulatory T-cells have been recognized: natural regulatory Tcells, Th3, Tr1, CD8+ Treg, natural killer like Treg (NKTreg) cells. Among various markers of Treg cells, Forkhead family transcription factor (FOXP3) as an intracellular protein is used for discrimination between activated T reg cells and activated T-cells. FOXP3 has a central role in production, thymocyte differentiation and function of regulatory Tcells. Several mechanisms have been indicated in regulation of T reg cells. As, the suppression of T-cells via regulatory T-cells is either mediated by Cell-cell contact and Immunosuppressive cytokines (TGF-Beta, IL-10) mediated.

APA, Harvard, Vancouver, ISO, and other styles

13

Bruneau, Julie, Danielle Canioni, Amédée Renand, Teresa Marafioti, Jennifer C. Paterson, Nadine Martin-Garcia, Philippe Gaulard, et al. "Regulatory T-Cell Depletion in Angioimmunoblastic T-Cell Lymphoma." American Journal of Pathology 177, no. 2 (August 2010): 570–74. http://dx.doi.org/10.2353/ajpath.2010.100150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Moltedo, Bruno, Saskia Hemmers, and Alexander Y. Rudensky. "Regulatory T Cell Ablation Causes Acute T Cell Lymphopenia." PLoS ONE 9, no. 1 (January 23, 2014): e86762. http://dx.doi.org/10.1371/journal.pone.0086762.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Chang, Jae-Hoon, and Yeonseok Chung. "Regulatory T Cells in B Cell Follicles." Immune Network 14, no. 5 (2014): 227. http://dx.doi.org/10.4110/in.2014.14.5.227.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Gliwiński, Mateusz, Dorota Iwaszkiewicz-Grześ, and Piotr Trzonkowski. "Cell-Based Therapies with T Regulatory Cells." BioDrugs 31, no. 4 (May 24, 2017): 335–47. http://dx.doi.org/10.1007/s40259-017-0228-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Chen, Shuming, Naoto Ishii, Shouji Ine, Syuichi Ikeda, Taku Fujimura, Lishomwa C. Ndhlovu, Pejman Soroosh, et al. "Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells." International Immunology 18, no. 2 (December 16, 2005): 269–77. http://dx.doi.org/10.1093/intimm/dxh366.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Young, M., and R. S. Geha. "Human Regulatory T-Cell Subsets." Annual Review of Medicine 37, no. 1 (February 1986): 165–72. http://dx.doi.org/10.1146/annurev.me.37.020186.001121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Papatriantafyllou, Maria. "Distilling regulatory T cell inducers." Nature Reviews Immunology 13, no. 8 (July 25, 2013): 547. http://dx.doi.org/10.1038/nri3506.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Kofler, David M., Markus Chmielewski, Heike Koehler, Tobias Riet, Patrick Schmidt, Gunter Rappl, Andreas Hombach, Michael Hallek, Clemens M. Wendtner, and Hinrich Abken. "Impact of Regulatory T Cells on Antigen Specific T Cell Response Using Recombinant Chimeric T Cell Receptors In Vivo." Blood 108, no. 11 (November 16, 2006): 5475. http://dx.doi.org/10.1182/blood.v108.11.5475.5475.

Full text

Abstract:

Abstract Recombinant T cell receptors with defined specificity against tumor cells are a promising experimental approach in the elimination of residual leukemia and lymphoma cells. It is so far unresolved whether regulatory T cells with suppressor activities impair the efficiency of cytolytic T cells grafted with a recombinant immunoreceptor. The frequency of regulatory T cells is highly increased in tumor patients and their suppressive function seems to play a role in the fail of an autologous T cell response against the malignant cells. In this study we analyzed the antigen-triggered, specific activation of receptor grafted T cells in the presence or absence of regulatory CD4+CD25high T cells. CD3+ T cells were grafted with CEA-specific immunoreceptors containing the CD3-zeta signaling domain for T cell activation. Co-cultivation of receptor grafted effector T cells together with regulatory T cells repressed proliferation of the effector cells and decreased IL-2 secretion. Secretion of IFN-gamma and IL-10 was not impaired. Interestingly, the cytotoxicity of grafted effector T cells towards CEA-expressing tumor cells was not impaired by regulatory T cells in vitro. To evaluate the relevance in vivo, we used a Crl:CD1 Nu/Nu mouse model to assess growth of CEA+ tumor cells in the presence of receptor grafted effector T cells and of regulatory T cells. Mice inoculated with tumor cells together with CD3+ effector T cells without immunoreceptor and regulatory T cells developed earlier tumors with faster growth kinetics compared to mice that were inoculated with tumor cells, CD3+ T cells and CD4+CD25- control T cells. Using effector T cells that were equipped with a recombinant CEA-specific CD3-zeta immunoreceptor, 2 of 5 mice developed a tumor in the presence of regulatory T cells while none of the mice developed a tumor in the absence of regulatory T cells. Taken together, regulatory T cells obviously impair an antigen-specific, anti-tumor T cell attack in vivo. This seems to be due to repression of proliferation of the effector T cells and not to diminished cytotoxicity. These findings have major impact on the design of clinical studies involving adoptively transferred effector T cells.

APA, Harvard, Vancouver, ISO, and other styles

21

Shevach, Ethan M. "Special regulatory T cell review: How I became a T suppressor/ regulatory cell maven." Immunology 123, no. 1 (January 2008): 3–5. http://dx.doi.org/10.1111/j.1365-2567.2007.02777.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Beissert, Stefan, Agatha Schwarz, and Thomas Schwarz. "Regulatory T Cells." Journal of Investigative Dermatology 126, no. 1 (January 2006): 15–24. http://dx.doi.org/10.1038/sj.jid.5700004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Kawahata, Kimito, Takeyuki Kanzaki, Mitsuru Imamura, Lisa Akahira, Kazuya Michishita, Makoto Dohi, and Kazuhiko Yamamoto. "Regulatory T cells in the control of T cell homeostasis." Inflammation and Regeneration 30, no. 6 (2010): 502–6. http://dx.doi.org/10.2492/inflammregen.30.502.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Berger, Carole L., Robert Tigelaar, Justine Cohen, Kavita Mariwalla, Jennifer Trinh, Nianci Wang, and Richard L. Edelson. "Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells." Blood 105, no. 4 (February 15, 2005): 1640–47. http://dx.doi.org/10.1182/blood-2004-06-2181.

Full text

Abstract:

Abstract Studies in an in vitro model of cutaneous T-cell lymphoma (CTCL) demonstrated that CTCL cell proliferation is stimulated by direct contact with autologous, immature dendritic cells (DCs), suggesting that CD4+ CTCL cell division is driven by antigens presented by DC major histocompatibility complex (MHC) class 2. We now report that the T-cell receptor (TCR) of the CD4+ CTCL cells is triggered after interaction with DCs loaded with apoptotic CTCL cells, as shown by reduced membrane expression of CD3 and the TCR, up-regulation of cytotoxic T lymphocyte antigen-4 (CTLA-4), and calcium mobilization. CTCL cells adopt a T-regulatory (Treg) phenotype expressing CD25/CTLA-4 and FoxP3 and secreting interleukin-10 (IL-10) and transforming growth factor-β (TGF-β). Treg CTCL cells suppress normal T-cell antigen-driven secretion of IL-2 and interferon-γ (IFN-γ). Blocking DC MHC class 2 expression or transport inhibited CTCL cell adoption of a Treg phenotype. Allogeneic CTCL cells or normal CD4 T cells served as sources of apoptotic material for CTCL cell conversion to a Treg phenotype. Conversion of CTCL cells to Treg cells may explain the anergic, immunosuppressive nature of the malignancy. (Blood. 2005;105:1640-1647)

APA, Harvard, Vancouver, ISO, and other styles

25

Shevach, Ethan M. "Control of T-cell responses by regulatory/suppressor T cells." Experimental Dermatology 12, no. 6 (December 2003): 913–14. http://dx.doi.org/10.1111/j.0906-6705.2003.0156d.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Gandhi, Roopali, Mauricio Farez, Yue Wang, Deneen Kozoriz, Francisco Quintana, and Howard Weiner. "Human LAP+ T Cells: A Novel Regulatory T Cell Subset." Clinical Immunology 135 (January 2010): S32. http://dx.doi.org/10.1016/j.clim.2010.03.100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Lechler, Robert, Jian-Guo Chai, Federica Marelli-Berg, and Giovanna Lombardi. "T–cell anergy and peripheral T–cell tolerance." Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 356, no. 1409 (May 29, 2001): 625–37. http://dx.doi.org/10.1098/rstb.2001.0844.

Full text

Abstract:

The discovery that T–cell recognition of antigen can have distinct outcomes has advanced understanding of peripheral T–cell tolerance, and opened up new possibilities in immunotherapy. Anergy is one such outcome, and results from partial T–cell activation. This can arise either due to subtle alteration of the antigen, leading to a lower–affinity cognate interaction, or due to a lack of adequate co–stimulation. The signalling defects in anergic T cells are partially defined, and suggest that T–cell receptor (TCR) proximal, as well as downstream defects negatively regulate the anergic T cell's ability to be activated. Most importantly, the use of TCR–transgenic mice has provided compelling evidence that anergy is an in vivo phenomenon, and not merely an in vitro artefact. These findings raise the question as to whether anergic T cells have any biological function. Studies in rodents and in man suggest that anergic T cells acquire regulatory properties; the regulatory effects of anergic T cells require cell to cell contact, and appear to be mediated by inhibition of antigen–presenting cell immunogenicity. Close similarities exist between anergic T cells, and the recently defined CD4 + CD25 + population of spontaneously arising regulatory cells that serve to inhibit autoimmunity in mice. Taken together, these findings suggest that a spectrum of regulatory T cells exists. At one end of the spectrum are cells, such as anergic and CD4 + CD25 + T cells, which regulate via cell–to–cell contact. At the other end of the spectrum are cells which secrete antiinflammatory cytokines such as interleukin 10 and transforming growth factor–β. The challenge is to devise strategies that reliably induce T–cell anergy in vivo , as a means of inhibiting immunity to allo– and autoantigens.

APA, Harvard, Vancouver, ISO, and other styles

28

Beltran, Brady E., Domingo Morales, Pilar Quinones, Roberto N. Miranda, Maitrayee Goswami, and Jorge J. Castillo. "Peripheral T-cell Lymphoma With a Regulatory T-cell Phenotype." Applied Immunohistochemistry & Molecular Morphology 20, no. 2 (March 2012): 196–200. http://dx.doi.org/10.1097/pai.0b013e318225189f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Basten, Antony, and Barbara Fazekas de St Groth. "Special regulatory T-cell review: T-cell dependent suppression revisited." Immunology 123, no. 1 (January 2008): 33–39. http://dx.doi.org/10.1111/j.1365-2567.2007.02772.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Baardman, Jeroen, and Esther Lutgens. "Regulatory T Cell Metabolism in Atherosclerosis." Metabolites 10, no. 7 (July 8, 2020): 279. http://dx.doi.org/10.3390/metabo10070279.

Full text

Abstract:

Regulatory T cells (Tregs) are capable of suppressing excessive immune responses to prevent autoimmunity and chronic inflammation. Decreased numbers of Tregs and impaired suppressive function are associated with the progression of atherosclerosis, a chronic inflammatory disease of the arterial wall and the leading cause of cardiovascular disease. Therefore, therapeutic strategies to improve Treg number or function could be beneficial to preventing atherosclerotic disease development. A growing body of evidence shows that intracellular metabolism of Tregs is a key regulator of their proliferation, suppressive function, and stability. Here we evaluate the role of Tregs in atherosclerosis, their metabolic regulation, and the links between their metabolism and atherosclerosis.

APA, Harvard, Vancouver, ISO, and other styles

31

Ninchoji, Takeshi, Hiroshi Kaito, and Kazumoto Iijima. "Regulatory T Cell and Nephrotic Syndrome." Nihon Shoni Jinzobyo Gakkai Zasshi 25, no. 2 (2012): 137–41. http://dx.doi.org/10.3165/jjpn.25.137.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Aandahl, Einar Martin, Knut Martin Torgersen, and Kjetil Taskén. "CD8+ regulatory T cells—A distinct T-cell lineage or a transient T-cell phenotype?" Human Immunology 69, no. 11 (November 2008): 696–99. http://dx.doi.org/10.1016/j.humimm.2008.08.291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Schwarz, Alexander, Marijana Schumacher, Daniel Pfaff, Kai Schumacher, Sven Jarius, Bettina Balint, Heinz Wiendl, Jürgen Haas, and Brigitte Wildemann. "Fine-Tuning of Regulatory T Cell Function: The Role of Calcium Signals and Naive Regulatory T Cells for Regulatory T Cell Deficiency in Multiple Sclerosis." Journal of Immunology 190, no. 10 (April 10, 2013): 4965–70. http://dx.doi.org/10.4049/jimmunol.1203224.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Reinhardt, Julia, Virag Sharma, Antigoni Stavridou, Annett Lindner, Susanne Reinhardt, Andreas Petzold, Mathias Lesche, Fabian Rost, Ezio Bonifacio, and Anne Eugster. "Distinguishing activated T regulatory cell and T conventional cells by single‐cell technologies." Immunology 166, no. 1 (March 2, 2022): 121–37. http://dx.doi.org/10.1111/imm.13460.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Baek, DS, TH Chung, YH Kim, SK Oh, KM So, and C. Park. "Changes in regulatory T cells in dogs with B-cell lymphoma and association with clinical tumour stage." Veterinární Medicína 62, No. 12 (December 4, 2017): 647–53. http://dx.doi.org/10.17221/7/2015-vetmed.

Full text

Abstract:

Among several mechanisms that allow tumours to disarm the host immune system and thus to evade or suppress protective anti-tumour immunity, an important role for CD4+CD25+FoxP3+ regulatory T cells (Tregs) has emerged. Numerous studies in humans have demonstrated increased Tregs in patients with carcinomas of the breast, lung, and pancreas, and this increased Treg has been correlated with poor prognosis. This study was performed (1) to investigate the percentage of Tregs in total lymphocytes of the peripheral blood in 12 canine patients with B cell lymphoma and (2) to investigate the change in the percentage of Tregs in canine lymphoma of different clinical tumour stages. On the flow cytometric analysis, the relative and absolute numbers of Tregs were significantly increased in 12 canine patients with B-cell lymphoma compared to five healthy beagles included in this study, and the greatest increases in the relative and absolute number of Tregs occurred in two dogs with more advanced World Health Organization clinical stages with bone marrow involvement compared to those in less advanced tumour stages without bone marrow involvement. This study provides basic information regarding the negative role of Treg recruitment in canine lymphoma patients and highlights the potential value of Treg levels as prognostic indicators in canine cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

36

Hall, Bruce M., Nirupama D. Verma, Giang T. Tran, and Suzanne J. Hodgkinson. "Distinct regulatory CD4+T cell subsets; differences between naïve and antigen specific T regulatory cells." Current Opinion in Immunology 23, no. 5 (October 2011): 641–47. http://dx.doi.org/10.1016/j.coi.2011.07.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Izcue, Ana, and Fiona Powrie. "Special regulatory T-cell review: regulatory T cells and the intestinal tract – patrolling the frontier." Immunology 123, no. 1 (January 2008): 6–10. http://dx.doi.org/10.1111/j.1365-2567.2007.02778.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Michael, Maria, Avichai Shimoni, and Arnon Nagler. "Regulatory T Cells in Allogeneic Stem Cell Transplantation." Clinical and Developmental Immunology 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/608951.

Full text

Abstract:

Growing evidence suggests that cellular adoptive immunotherapy is becoming an attractive though challenging approach in regulating tumor immunity and alloresponses in clinical transplantation. Naturally arising CD4+CD25+Foxp3+ regulatory T cells (Treg) have emerged as a key component in this regard. Over the last decade, a large body of evidence from preclinical models has demonstrated their crucial role in auto- and tumor immunity and has opened the door to their “first-in-man” clinical application. Initial studies in clinical allogeneic stem cell transplantation are very encouraging and may pave the way for other applications. Further improvements in Tregex vivoorin vivoexpansion technologies will simplify their global clinical application. In this review, we discuss the current knowledge of Treg biology and their potential for cell-based immunotherapy in allogeneic stem cell transplantation.

APA, Harvard, Vancouver, ISO, and other styles

39

Liu, Sai, Dongjuan Liu, Jing Li, Dunfang Zhang, and Qianming Chen. "Regulatory T cells in oral squamous cell carcinoma." Journal of Oral Pathology & Medicine 45, no. 9 (April 15, 2016): 635–39. http://dx.doi.org/10.1111/jop.12445.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Wang, Yi, Yushui Ma, Ying Fang, Shengdi Wu, Lili Liu, Da Fu, and Xizhong Shen. "Regulatory T cell: a protection for tumour cells." Journal of Cellular and Molecular Medicine 16, no. 3 (February 28, 2012): 425–36. http://dx.doi.org/10.1111/j.1582-4934.2011.01437.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Sawasdikosol, Sansana, Renyuan Zha, Timothy S. Fisher, Saba Alzabin, and Steven J. Burakoff. "HPK1 Influences Regulatory T Cell Functions." ImmunoHorizons 4, no. 7 (July 1, 2020): 382–91. http://dx.doi.org/10.4049/immunohorizons.1900053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

TANAKA, Satoshi, and Shimon SAKAGUCHI. "Regulatory T cell and autoimmune diseases." Japanese Journal of Clinical Immunology 28, no. 5 (2005): 291–99. http://dx.doi.org/10.2177/jsci.28.291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Jiang, Shuiping, Robert I. Lechler, and Giovanna Lombardi. "CD4+CD25+regulatory T-cell therapy." Expert Review of Clinical Immunology 2, no. 3 (May 2006): 387–92. http://dx.doi.org/10.1586/1744666x.2.3.387.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

CATON, ANDREW J., CRISTINA COZZO, JOSEPH LARKIN, MELISSA A. LERMAN, ALINA BOESTEANU, and MARTHA S. JORDAN. "CD4+CD25+Regulatory T Cell Selection." Annals of the New York Academy of Sciences 1029, no. 1 (December 2004): 101–14. http://dx.doi.org/10.1196/annals.1309.028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Tang, Qizhi, and Karim Lee. "Regulatory T-cell therapy for transplantation." Current Opinion in Organ Transplantation 17, no. 4 (August 2012): 349–54. http://dx.doi.org/10.1097/mot.0b013e328355a992.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

MacDonald, Katherine G., Paul C. Orban, and Megan K. Levings. "T regulatory cell therapy in transplantation." Current Opinion in Organ Transplantation 17, no. 4 (August 2012): 343–48. http://dx.doi.org/10.1097/mot.0b013e328355aaaf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Singer, Benjamin D. "Opening the Regulatory T Cell Toolbox." American Journal of Respiratory Cell and Molecular Biology 57, no. 2 (August 2017): 137–38. http://dx.doi.org/10.1165/rcmb.2017-0130ed.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Konopacki, Catherine, George Plitas, and Alexander Rudensky. "Reigning in regulatory T-cell function." Nature Biotechnology 33, no. 7 (July 2015): 718–19. http://dx.doi.org/10.1038/nbt.3285.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

BODAGHI, B. "Regulatory T cell therapy for uveitis." Acta Ophthalmologica 90 (August 6, 2012): 0. http://dx.doi.org/10.1111/j.1755-3768.2012.3643.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Wei, Shuang, Ilona Kryczek, and Weiping Zou. "Regulatory T-cell compartmentalization and trafficking." Blood 108, no. 2 (July 15, 2006): 426–31. http://dx.doi.org/10.1182/blood-2006-01-0177.

Full text

Abstract:

CD4+CD25+FOXP3+ regulatory T cells (CD4+ Treg cells) are thought to differentiate in the thymus and immigrate from the thymus to the periphery. Treg cells can regulate both acquired and innate immunity through multiple modes of suppression. The cross-talk between Treg cells and targeted cells, such as antigen-presenting cells (APCs) and T cells, is crucial for ensuring suppression by Treg cells in the appropriate microenvironment. Emerging evidence suggests that Treg compartmentalization and trafficking may be tissue or/and organ specific and that distinct chemokine receptor and integrin expression may contribute to selective retention and trafficking of Treg cells at sites where regulation is required. In this review, the cellular and molecular signals that control specialized migration and retention of Treg cells are discussed.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Regulatory T cell'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles